LENZ Therapeutics, Inc. Logo

LENZ Therapeutics, Inc.

Develops a prescription eye drop for presbyopia, the age-related loss of near vision.

LENZ | US

Overview

Corporate Details

ISIN(s):
US38870X1046 (+1 more)
LEI:
Country:
United States of America
Address:
201 LOMAS SANTA FE DRIVE, SUITE 300, 92075 SOLANA BEACH
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

LENZ Therapeutics, Inc. is a late-stage biopharmaceutical company focused on the development and commercialization of innovative ophthalmic therapies to improve vision. The company's lead product is VIZZ™ (aceclidine ophthalmic solution) 1.44%, a prescription eye drop for the treatment of presbyopia, the age-related loss of near vision. According to the company, VIZZ is the first FDA-approved aceclidine-based therapy for this condition, targeting a significant market of approximately 128 million people in the United States and 1.8 billion globally. LENZ Therapeutics aims to provide a best-in-class pharmaceutical solution that offers freedom from reading glasses for a broad patient population.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all LENZ Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for LENZ Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for LENZ Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
IOVANCE BIOTHERAPEUTICS, INC. Logo
Developing personalized T-cell immunotherapies (TIL) to fight solid tumors and blood cancers.
United States of America IOVA
Ipsen Logo
Developing innovative medicines for Oncology, Rare Diseases, and Neuroscience.
France IPN
IRLAB Therapeutics Logo
Developing novel drugs for Parkinson's disease and other neurodegenerative CNS disorders.
Sweden IRLAB
IRONWOOD PHARMACEUTICALS INC Logo
Develops and commercializes therapies for GI diseases like IBS-C and chronic constipation.
United States of America IRWD
ISU Abxis Co., Ltd. Logo
Developing antibody-based immunotherapies for oncology and rare diseases.
South Korea 086890
Iterum Therapeutics plc Logo
Develops novel oral & IV anti-infectives to combat multi-drug resistant pathogens.
United States of America ITRM
IVF HARTMANN Holding AG Logo
Produces and distributes medical supplies, wound care, and hygiene items for global healthcare.
Switzerland VBSN
Jade Biosciences, Inc. Logo
Clinical-stage biotech developing therapies for autoimmune and inflammatory diseases.
United States of America JBIO
Jaguar Health, Inc. Logo
Develops plant-based, non-opioid GI therapies for humans and animals.
United States of America JAGX
Janux Therapeutics, Inc. Logo
Developing tumor-activated immunotherapies to treat cancer while minimizing systemic toxicities.
United States of America JANX

Talk to a Data Expert

Have a question? We'll get back to you promptly.